Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001213900-25-021200
Filing Date
2025-03-06
Accepted
2025-03-06 16:23:54
Documents
5
Effectiveness Date
2025-03-06

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT ea0233000-s8_oruka.htm S-8 35683
2 OPINION OF GIBSON, DUNN & CRUTCHER LLP ea023300001ex5-1_oruka.htm EX-5.1 9625
3 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ea023300001ex23-1_oruka.htm EX-23.1 1466
4 FILING FEE TABLE ea023300001ex-fee_oruka.htm EX-FILING FEES 13717
5 GRAPHIC ex5-1_001.jpg GRAPHIC 2675
  Complete submission text file 0001213900-25-021200.txt   65648
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-285601 | Film No.: 25715617
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)